UnknownPhase 2NCT03171818

Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration

Studying Partial androgen insensitivity syndrome

Last synced from ClinicalTrials.gov May 16, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: UMC Utrecht
Principal Investigator: Manon Benders, MD PhD
UMC Utrecht
Intervention: Darbepoetin Alfa(drug)
Enrollment: 80 enrolled
Eligibility: All sexes
Timeline: 2017 – 2025

Study locations (1)

Wilhelmina Childrens Hostpital/University Medical Center Utrecht, Utrecht, Netherlands

Collaborators

Alberta Children's Hospital · The Hospital for Sick Children

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03171818 on ClinicalTrials.gov

← Back to all trials